THE TAPE
TNDM · Medical Instruments · $1.3B

Tandem Diabetes Care, Inc.

$18.48▼ −7.92%
Last close
Relative strength
50RS
of 99, against every stock▲ +19 on the month
Powering up
Unconfirmed
+4.1%
six months against Medical Instruments
52-week range
−37.7%
from the high
$12.26$29.65
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +14% on a year ago
Why it is on no screen

TNDM is off the screens on 2 checks.

A base has formed8.8 weeks, from 17.71 to 24.50.
Long enough to count8.8 weeks against 3 needed.
Shallow enough27.7% deep against 35% allowed.
Close to its pivot-24.6% from the pivot; listed down to -20%.
Relative strengthRS 50 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$17.90
-3.1% · tested 5× · last 9 sessions ago
Resistance above
$20.39
+10.3% · tested 6× · last 7 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Tandem Diabetes Care, Inc. is not on any of the screens right now. Its relative strength rating is 50, and it sits in Medical Instruments.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
+9.3%
Three months against its industry
-22.3%
Six months against its industry
+4.1%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 19.8% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$1.1B
+13.8% year on year
Operating margin
-2.4%
gross 56.6%
Net margin
-4.6%
Free cash flow
$-36.3M
-2.8% of market cap
Price to sales
1.20×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Cash flow is the weak point of the quarter.
Revenue
$283.7M
+11.4% QoQ · +13.8% YoY
Gross margin
56.5%
-0.4 pts QoQ
Net income
−$7.1M
Loss
Free cash flow
−$5.5M
Burning · 13q runway

What the numbers say

  • Revenue +13.8% year over year, +11.4% on the quarter
  • Gross margin 56.5%, -0.4 points on the quarter
  • Weak: Net loss $7M, narrower than $21M last quarter
  • Weak: Burning cash: operating cash flow -$819K, free cash flow -$6M, better than -$39M last quarter · 13 quarters of cash at this burn
  • Weak: Growth externally funded: capex $5M against operating cash flow -$819K
  • Net debt $531M · cash $73M
Revenue by quarter
Free cash flow
Net income
shares +3.0% in a year · net debt $530.5M

What is not obvious

  • Weak: Cash flow quality: operating cash flow -$819K included a $2M deferred-revenue inflow; -$3M without it. Customers paid ahead of delivery
  • Weak: Stock compensation $16M added back against negative operating cash flow
  • Weak: Interest $2M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $7M, narrower than $21M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-14
above 20d & 50d on 1.8x volume at 20.07
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-14
+14.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-13
-6.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-10
+7.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-07
below 20d & 50d on 2.5x volume at 16.91
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-07
-6.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-07
-6.0% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Unusual volumeTape · 2026-11-07
4.2 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
1
$32,555 total

Sold: TWOMEY CHRISTOPHER J.

Not counted above: 32 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-27 TWOMEY CHRISTOPHER J · Directoroption exercise1,700$32,300
2026-10-27 TWOMEY CHRISTOPHER J · Directorsell1,700$32,555
2026-10-15 Kyrillos Jean-Claude · EVP & Chief Operating Officeroption exercise3,637
2026-10-15 Kyrillos Jean-Claude · EVP & Chief Operating Officerwithheld for tax1,926$31,818
2026-08-15 Vosseller Leigh · EVP & CHIEF FINANCIAL OFFICERoption exercise1,496
2026-08-15 Vosseller Leigh · EVP & CHIEF FINANCIAL OFFICERwithheld for tax537$12,201
2026-08-15 Vosseller Leigh · EVP & CHIEF FINANCIAL OFFICERoption exercise2,624
2026-08-15 Vosseller Leigh · EVP & CHIEF FINANCIAL OFFICERwithheld for tax942$21,402

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy11
Hold12
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Tandem Diabetes Care, Inc. (TNDM) — The Tape